Usefulness of the 2-year iodine-123 metaiodobenzylguanidine-based risk model for post-discharge risk stratification of patients with acute decompensated heart failure

Tamaki, Shunsuke; Yamada, Takahisa; Watanabe, Tetsuya; Morita, Takashi; Kawasaki, Masato; Kikuchi, Atsushi; Kawai, Tsutomu; Seo, Masahiro; Nakamura, Jun; Kayama, Kiyomi; Sakamoto, Daisuke; Ueda, Kumpei; Kogame, Takehiro; Tamura, Yasuaki; Fujita, Takeshi; Nishigaki, Keisuke; Fukuda, Yuto; Kokubu, Yuki; Fukunami, Masatake

doi:10.1007/s00259-021-05663-y

Cited by 6 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have validated this prognostic MIBG risk model, demonstrating its predictive utility for mortality at 2 years ( 17 , 18 ). We validated this model for 5-year mortality risk in our database by comparing the cumulative event rates in the tertiles of mortality risk.…”

Section: Discussionmentioning

confidence: 99%

Validation of a Five-Year Prognostic Model Using <sup>123</sup>I-metaiodobenzylguanidine Scintigraphy in Patients with Heart Failure

Ishibashi

Kasama

Kurabayashi

et al. 2023

Annals of Nuclear Cardiology

View full text Add to dashboard Cite

Background : 123 I-metaiodobenzylguanidine (MIBG) scintigraphy evaluates the severity and prognosis of patients with heart failure. A prognostic model has been proposed using a multicenter study data of 123 I-MIBG scintigraphy. We evaluated the usefulness of the model using a database. Methods : The study included 208 patients with noncompensated heart failure requiring hospitalization. 123 I-MIBG scintigraphy and echocardiography were performed predischarge and 6 months postdischarge. The 5-year mortality rate was calculated by the model and classified into tertiles. Results : In 208 patients, 56 cardiac deaths occurred within the observation period (median, 4.83 years). In the evaluation of predischarge parameters, the predicted 5-year mortality was 15.5% ± 5.0%, 33.5% ± 3.9%, and 51.2% ± 8.2%, and 11 (16.2%), 18 (27.3%), and 27 (36.5%) cardiac deaths occurred in groups 1, 2, and 3, respectively. At the 6-month postdischarge evaluation, the estimated mortality was 8.2% ± 2.2%, 18.5% ± 4.8%, and 43.0% ± 12.1%, and 6 (9.4%), 21 (29.2%), and 29 (40.3%) cardiac deaths occurred, respectively. The predischarge Kaplan-Meier survival analysis showed significant difference between groups 1 and 3 (P value 0.014). Moreover, the 6-month postdischarge evaluation showed significant difference between group 1 and 2, and between groups 1 and 3 (P value 0.016, <0.001, respectively). For groups 1 and 3, the 6-month postdischarge difference was more significant than the predischarge difference (Chi-square 16.7 and 8.1, respectively). Conclusions : The prognostic model using 123 I-MIBG scintigraphy was useful in predicting mortality risk in patients with heart failure. The estimated mortality at 6 months postdischarge was more useful than the predischarge estimation for heart failure hospitalization.

show abstract

Section: Discussionmentioning

confidence: 99%

Validation of a Five-Year Prognostic Model Using <sup>123</sup>I-metaiodobenzylguanidine Scintigraphy in Patients with Heart Failure

Ishibashi

Kasama

Kurabayashi

et al. 2023

Annals of Nuclear Cardiology

View full text Add to dashboard Cite

show abstract

“…HF is frequently associated with comorbidities and chronic conditions, such as diabetes, obesity, kidney dysfunction, and sleep-disordered breathing (SDB), that may affect cardiac adrenergic innervation, with a negative impact on disease progression and outcome [9]. In addition, cardiac 123 I-MIBG single photon emission tomography (SPECT) imaging may also provide prognostic data in non-ischemic acute decompensated HF patients and preserved ejection fraction (HFpEF) [10,11].…”

Section: Introductionmentioning

confidence: 99%

123I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervation

Gargiulo

Acampa

Asile

et al. 2022

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Heart failure (HF) is a primary cause of morbidity and mortality worldwide, with significant impact on life quality and extensive healthcare costs. Assessment of myocardial sympathetic innervation function plays a central role in prognosis assessment in HF patients. The aim of this review is to summarize the most recent evidence regarding the clinical applications of iodine-123 metaiodobenzylguanidine (123I-MIBG) imaging in patients with HF and related comorbidities. Methods A comprehensive literature search was conducted on PubMed and Web of Science databases. Articles describing the impact of 123I-MIBG imaging on HF and related comorbidities were considered eligible for the review. Results We collected several data reporting that 123I-MIBG imaging is a safe and non-invasive tool to evaluate dysfunction of cardiac sympathetic neuronal function and to assess risk stratification in HF patients. HF is frequently associated with comorbidities that may affect cardiac adrenergic innervation. Furthermore, HF is frequently associated with comorbidities and chronic conditions, such as diabetes, obesity, kidney disease and others, that may affect cardiac adrenergic innervation. Conclusion Comorbidities and chronic conditions lead to more severe impairment of sympathetic nervous system in patients with HF, with a negative impact on disease progression and outcome. Cardiac imaging with 123I-MIBG can be a useful tool to reduce morbidity and prevent adverse events in HF patients.

show abstract

Remote ischemic periconditioning suppresses cardiac sympathetic activation in acute myocardial infarction: a randomized controlled trial

Kondo,

Seo,

Watanabe

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Usefulness of the 2-year iodine-123 metaiodobenzylguanidine-based risk model for post-discharge risk stratification of patients with acute decompensated heart failure

Cited by 6 publications

References 36 publications

Validation of a Five-Year Prognostic Model Using <sup>123</sup>I-metaiodobenzylguanidine Scintigraphy in Patients with Heart Failure

Validation of a Five-Year Prognostic Model Using <sup>123</sup>I-metaiodobenzylguanidine Scintigraphy in Patients with Heart Failure

123I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervation

Remote ischemic periconditioning suppresses cardiac sympathetic activation in acute myocardial infarction: a randomized controlled trial

Contact Info

Product

Resources

About